The assets acquired include intellectual property, product inventory and clinical data as well as all technologies related to the CellSearch system, claimed to be the first diagnostic test to automate the detection and enumeration of circulating tumor cells, cancer cells that detach from solid tumors and enter the blood stream.
The CellSearch system is currently cleared for the prognosis and monitoring of patients with metastatic breast, metastatic colorectal and metastatic prostate cancer.
As part of the agreement, Veridex also received all technologies related to Repeat-Free Poseidon fluorescent in-situ hybridization probes.
Ken Berlin, general manager of Veridex, said: “This asset purchase ensures the role of CellSearch in the future of Veridex. It underscores our continued commitment to the medical community and to cancer patients who may benefit from technologies like the CellSearch system.”